RecruitingNCT05342493

Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use

AJOVY Subcutaneous Injection Long-term Specified Use-results Survey

Sponsor

Otsuka Pharmaceutical Co., Ltd.

Enrollment

1,000 participants

Start Date

Apr 20, 2022

Study Type

OBSERVATIONAL

Conditions

Migraine Disorders

Summary

To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.

Eligibility

Min Age: 18 Years

Inclusion Criteria1

Exclusion Criteria1

patients with a known hypersensitivity to components of AJOVY

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFremanezumab 225 Mg/1.5 mL Subcutaneous Solution

The usual adult dose is 225 mg of fremanezumab (genetical recombination) administered subcutaneously as a single dose once every 4 weeks or 675 mg administered subcutaneously as a single dose once every 12 weeks.